The transcription factor nuclear factor kappa B (NF-jB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IjBa-dn) where the classical NF-jB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IjBa) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-jB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-jB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IjBa-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IjBa-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IjBadn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-jB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain. Ó
a b s t r a c t
The transcription factor nuclear factor kappa B (NF-jB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IjBa-dn) where the classical NF-jB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IjBa) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-jB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-jB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IjBa-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IjBa-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IjBadn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-jB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain.
Ó 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Introduction
Nuclear factor kappa B (NF-jB) is a ubiquitous transcription factor which regulates the expression for many genes (e.g., cytokines, chemokines, iNOS) that are important in immunity, inflammation, central nervous system (CNS) injury, and neuropathic pain [15, 18, 20, 26] . In non-stimulated cells, NF-jB dimers are maintained in the cytosol by binding to the inhibitors of jB (IjBs; e.g., IjBa, IjBb, and IjBe). In response to cell stimulation (e.g., cytokines, glutamate, oxidative damage, growth factors), a multisubunit kinase complex, the IjB kinase (IKK), is rapidly activated and phosphorylated in the N-terminal regulatory domain of the IjBs. This signals the ubiquitin proteasome pathway to degrade IjBa, releasing activated NF-jB which can translocate to the nucleus and initiate transcription of mediators that are involved in the pathogenesis of neuropathic pain.
While suppression of NF-jB appears to be an attractive concept in the approach to treating pain and inflammation, unselective and complete inhibition of NF-jB may lead to deleterious effects in terms of cell survival [18] . It has been postulated that strategies to selectively inhibit NF-jB activity would be of great benefit in terms of attenuating pain and inflammation while reducing unwanted side effects [18, 26] . In a recent review by Niederberger et al.
[18], a novel approach for pain therapy includes strategies which prevent IjB phosphorylation and selectively inactivate NFjB transcription. For example, pharmacological agents that specifically inhibit IKK have been shown to reduce mechanical and thermal hyperalgesia after CCI and zymosan induced paw inflammation in rats [26] .
To address the issue of selective inactivation of NF-jB as a modality to treat pain, we utilized a transgenic mouse model that overexpresses the dominant negative (dn) form of the inhibitor of kappa B alpha (IjBa) in glial cells, under the control of the glial fibrillary acidic protein (GFAP) promoter [3] . The transgene, GFAP-IjBa-dn, is present not only in astrocytes in the CNS, which
